Reducing the price of new hepatitis C drugs in the Tuscany region of Italy

In most European countries, regulatory agencies are engaged in approving reimbursement schemes for the new interferon-free direct antiviral agents (DAAs) for hepatitis C.1 2 The degree of reimbursement differs across countries and sometimes between regions of the same country.